European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

K. Hübel, M. M. Fresen, J. F. Apperley, G. W. Basak, K. W. Douglas, I. H. Gabriel, C. Geraldes, O. Jaksic, Z. Koristek, N. Kröger, F. Lanza, R. M. Lemoli, G. Mikala, D. Selleslag, N. Worel, M. Mohty, R. F. Duarte

Research output: Article

45 Citations (Scopus)

Abstract

The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.

Original languageEnglish
Pages (from-to)1046-1050
Number of pages5
JournalBone Marrow Transplantation
Volume47
Issue number8
DOIs
Publication statusPublished - aug. 2012

Fingerprint

Hematopoietic Stem Cell Mobilization
Multiple Myeloma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Compassionate Use Trials
Mantle-Cell Lymphoma
Follicular Lymphoma
Blood Component Removal
Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cells
JM 3100
Granulocytes
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. / Hübel, K.; Fresen, M. M.; Apperley, J. F.; Basak, G. W.; Douglas, K. W.; Gabriel, I. H.; Geraldes, C.; Jaksic, O.; Koristek, Z.; Kröger, N.; Lanza, F.; Lemoli, R. M.; Mikala, G.; Selleslag, D.; Worel, N.; Mohty, M.; Duarte, R. F.

In: Bone Marrow Transplantation, Vol. 47, No. 8, 08.2012, p. 1046-1050.

Research output: Article

Hübel, K, Fresen, MM, Apperley, JF, Basak, GW, Douglas, KW, Gabriel, IH, Geraldes, C, Jaksic, O, Koristek, Z, Kröger, N, Lanza, F, Lemoli, RM, Mikala, G, Selleslag, D, Worel, N, Mohty, M & Duarte, RF 2012, 'European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization', Bone Marrow Transplantation, vol. 47, no. 8, pp. 1046-1050. https://doi.org/10.1038/bmt.2011.216
Hübel, K. ; Fresen, M. M. ; Apperley, J. F. ; Basak, G. W. ; Douglas, K. W. ; Gabriel, I. H. ; Geraldes, C. ; Jaksic, O. ; Koristek, Z. ; Kröger, N. ; Lanza, F. ; Lemoli, R. M. ; Mikala, G. ; Selleslag, D. ; Worel, N. ; Mohty, M. ; Duarte, R. F. / European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 8. pp. 1046-1050.
@article{b7ba118e484b4d59bd39dbfb12f33843,
title = "European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization",
abstract = "The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6{\%}; 5.0 × 10 6 CD34 cells/kg: 32.0{\%}) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8{\%}; 5.0 × 10 6 CD34 cells/kg: 12.6{\%}; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5{\%}; 5.0 × 10 6 CD34 cells/kg: 22.2{\%}) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.",
keywords = "European centers, lymphoma subtypes, mobilization, plerixafor",
author = "K. H{\"u}bel and Fresen, {M. M.} and Apperley, {J. F.} and Basak, {G. W.} and Douglas, {K. W.} and Gabriel, {I. H.} and C. Geraldes and O. Jaksic and Z. Koristek and N. Kr{\"o}ger and F. Lanza and Lemoli, {R. M.} and G. Mikala and D. Selleslag and N. Worel and M. Mohty and Duarte, {R. F.}",
year = "2012",
month = "8",
doi = "10.1038/bmt.2011.216",
language = "English",
volume = "47",
pages = "1046--1050",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

AU - Hübel, K.

AU - Fresen, M. M.

AU - Apperley, J. F.

AU - Basak, G. W.

AU - Douglas, K. W.

AU - Gabriel, I. H.

AU - Geraldes, C.

AU - Jaksic, O.

AU - Koristek, Z.

AU - Kröger, N.

AU - Lanza, F.

AU - Lemoli, R. M.

AU - Mikala, G.

AU - Selleslag, D.

AU - Worel, N.

AU - Mohty, M.

AU - Duarte, R. F.

PY - 2012/8

Y1 - 2012/8

N2 - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.

AB - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.

KW - European centers

KW - lymphoma subtypes

KW - mobilization

KW - plerixafor

UR - http://www.scopus.com/inward/record.url?scp=84864883480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864883480&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.216

DO - 10.1038/bmt.2011.216

M3 - Article

C2 - 22080971

AN - SCOPUS:84864883480

VL - 47

SP - 1046

EP - 1050

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -